Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing

BACKGROUND: Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients eligible for early-phase clinical trials. In this study the...

Descripción completa

Detalles Bibliográficos
Autores principales: Pruis, Melinda A., Groenendijk, Floris H., Badloe, K. Sangeeta, van Puffelen, Andrea, Robbrecht, Debbie, Dinjens, Winand N. M., Sleijfer, Stefan, Dingemans, Anne-Marie C., von der Thüsen, Jan H., Roepman, Paul, Lolkema, Martijn P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381598/
https://www.ncbi.nlm.nih.gov/pubmed/35606463
http://dx.doi.org/10.1038/s41416-022-01841-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381598/
https://www.ncbi.nlm.nih.gov/pubmed/35606463
http://dx.doi.org/10.1038/s41416-022-01841-3

Ejemplares similares